N/A N=80 Knee Bracing for People With Patellofemoral Osteoarthritis
Knee Osteoarthritis
Primary: Change in Pain on the VIsual Analog Scale (VAS) — -.068 change in units on a scale from baseline
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=62 Factors Associated With Radiographic Pathophysiology for Trapeziometacarpal Arthrosis in Patients Not Seeking Care for This Condition
Trapeziometacarpal Arthrosis
Primary: Factors Associated With Eaton Classification of Trapeziometacarpal Arthrosis: Age — 61; 66; 75 Years
Phase 3 N=164 A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis
Knee Osteoarthritis
Primary: Change From Baseline in WOMAC VA3.1 Pain Subscale Score at Month 6 — -23.6; -14.1 mm — p=0.141
Phase 2 N=41 A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale
Osteoarthritis, Knee
Primary: Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period — -12.6; -13.6; -11.7; -2.3 Scores on a scale
N/A N=3,000 Development of an Osteoarthritis (OA) Care Plan to Improve Process and Quality of OA Treatment Decisions
Osteo Arthritis Knee · Osteoarthritis, Hip
Primary: Differences in Decision Conflict Scale With ASK vs Usual Care — 25.1; 26.0 Score on a scale
N/A N=7 Preventing Posttraumatic Osteoarthritis With Physical Activity Promotion
Anterior Cruciate Ligament Injuries · Exercise · Cartilage, Articular
Primary: T1rho Relaxation Times in the Medial Femoral Condyle at Baseline — 53.48 ms
Phase 3 N=100 Efficacy and Safety Study of Glucosamine/Chondroitin Sulfate to Patients Treatment With Osteoarthrosis of the Knee
Osteoarthritis of the Knee
Primary: To Assess the Efficacy and Safety of the Association of Glucosamine Sulphate 500 mg/Chondroitin Sulphate 400 mg (Eurofarma) in the Treatment of Osteoarthritis, Compared…
N/A N=101 Role of Bone in Knee Osteoarthritis (OA)
Osteoarthritis, Knee
Primary: Number of Participants With Viable Specimens for Genetic Analysis — 14 participants
Phase 2 N=74 Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial
Osteoarthritis, Knee
Primary: Number of Participants Experiencing One or More Treatment-Emergent Adverse Event — 28; 33 Participants — p=>0.9
N/A N=40 Muscle Property, Alignment and Joint Loading in People With Knee Osteoarthritis
Osteoarthritis, Knee
Primary: Change of External Knee Adduction Moment as Assessed by Visual Motion Analysis System — 0.50 Nm/kg
Phase 3 N=380 Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis
Osteoarthritis · Osteoarthritis, Knee
Primary: Change Form Baseline in WOMAC A Pain Subscale — -11.14; -11.82 cm — p=<0.025
N/A N=23 In Vivo Three-Dimensional Determination of Osteoarthritis Brace Effectiveness
Osteoarthritis, Knee
Primary: Medial Condylar Separation With Brace — 0.60 mm
N/A N=300 Patient and Provider Interventions for Managing Osteoarthritis in Primary Care
Osteoarthritis
Primary: Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) — 48.4; 48.4; 43.5; 41.2 units on a scale — p=0.158
N/A N=58 Mobility Optimization Through Velocity Exercise
Knee Osteoarthritis
Primary: Change in Basic Lower Limb Function (Late Life Function Index) Late Life Function and Disability Instrument — 3.3; -1.0; 3.1; 0.8 units on a scale
N/A N=90 Resistance Exercise and Knee Osteoarthritis Pain, Functional Impairment and Cartilage Turnover
Knee Osteoarthritis
Primary: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC Score); Change From Baseline at 4 Months — 27.1; 33.3; 28.9; 26.7 units on a scale
N/A N=1,261 Survey of Osteoarthritis Real World Therapies (MK-0663-140)
Osteoarthritis
Primary: Percentage of Participants Who Reported Adequate vs. Inadequate Pain Relief at Baseline — 46.2; 53.8 Percentage of Participants
N/A N=25 A Biomarker Stress Test for Detection of Early Osteoarthritis
Osteoarthritis
Primary: Change at 6 Months From Baseline in First Peak Knee Adduction Moment (KAM): (6 Month Value - Baseline) — -0.19 %Bw*Ht
Phase 2 N=260 Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis
Osteoarthritis of the Knee
Primary: Pain When Walking On A Flat Surface — 0; 1; 8; 4 Participants
N/A N=50 Osteoarthritis Structural Changes Assessed by Magnetic Resonance Imaging and Neuropathic Pain in Knee Osteoarthritis
Neuropathic Pain · Knee Osteoarthritis
Primary: Osteoarthritis Structural Changes Assessed by Quantitative Magnetic Resonance Imaging With and Without Neuropathic Pain — 14; 7; 5; 1 participants
Phase 4 N=500 Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)
Pain
Primary: The Percentage of Participants Achieving ≥30% Decrease From Baseline in Pain Intensity as Measured by WOMAC (Western Ontario and McMaster Universities Osteoarthritis…
N/A N=41 Hip Osteoarthritis: Effects of Exercise Programs on Pain and Disability
Hip Osteoarthritis
Primary: Change in 6-minute Walk Test — 22; 49 meters
Phase 4 N=150 Effects on the Pain of an Infiltration by Acid Hyaluronic Association and Corticoids Versus Only Corticoids in the Rhizarthrosis.
Rhizarthrosis
Primary: Analogical Visual Scale of Pain (VAS) — -1.66; -2.65 centimeter
N/A N=65 Intra-articular Polyacrylamide Hydrogel in Gonarthrosis
Osteoarthritis
Primary: Change in the Total WOMAC Score (WOMAC-T) — 649.80; 1091.70; 767.47; 293.60 score on a scale — p=0.004
N/A N=144 Intra-articular Polyacrylamide Hydrogel in Knee Osteoarthritis
Osteoarthritis
Primary: Change of the Total WOMAC Score (WOMAC-T) — -624.12; -444.82; -605.61; -426.31 score on a scale — p=0.00030
N/A N=23 Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
Knee Osteoarthristis
Primary: Cross-sectional Area (CSA) of Muscle Fibers — 2680; 2377; 2028; 1882 micron squared
Phase 3 N=163 Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand
Osteoarthrosis
Primary: Change in Global Spontaneous Pain Intensity of Target Hand — -20; -11.3 mm — p=0.016
Phase 2 N=21 Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee
Osteoarthritis of the Knee
Primary: Change in Synovitis — 9.8 units on a scale
N/A N=121 MRI of Infrapatellar Fat Pad in Osteoarthritis
Osteoarthritis
Primary: Infrapatellar Fat Pad Volume in MRI — 25154.96; 29202.39 mm^3
N/A N=11 Evaluation of Intra-articular Injection of Autologous Protein Solution ("APS(TM)") for the Treatment of Osteoarthritis (OA)
Gonarthrosis · Knee Osteoarthritis · Osteoarthritis
Primary: Number of Adverse Events — 22 Adverse Events (AEs)
N/A N=351 Comparing Surgery Versus Standard Physical Therapy in Treating People With a Meniscal Tear and Osteoarthritis
Osteoarthritis
Primary: WOMAC Functional Status - Difference From Baseline — 20.9; 18.5 Score — p=0.26